Patents
Literature
13 results about "Muse cell" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A Muse cell (Multi-lineage differentiating stress enduring cell) is an endogenous non-cancerous pluripotent stem cell. They reside in the connective tissue of nearly every organ, bone marrow and peripheral blood. They are collectable from commercially obtainable mesenchymal cells such as human fibroblasts, bone marrow-mesenchymal stem cells and adipose-derived stem cells. Muse cells are able to generate cells representative of all three germ layers from a single cell both spontaneously and under cytokine induction. Expression of pluripotency genes and triploblastic differentiation are self-renewable over generations. Muse cells do not undergo teratoma formation when transplanted into a host environment in vivo. This can be explained in part by their intrinsically low telomerase activity, eradicating the risk of tumorigenesis through unbridled cell proliferation. They were discovered in 2010 by Mari Dezawa and her research group. Clinical trials for acute myocardial infarction, stroke, epidermolysis bullosa and spinal cord injury are conducted by Life Science Institute, Inc., a group company of Mitsubishi Chemical Holdings company.
Therapy for interstitial cystitis by pluripotent stem cells
The purpose of the present invention is to provide a novel medical application using pluripotent stem cells in regenerative medicine. The present invention provides a cell formulation and pharmaceutical composition that are for amelioration and therapy for frequent urination and bladder pain caused by the inflammation of the bladder and that contain SSEA-3 positive pluripotent stem cells isolated from cultured mesenchymal cells or a mesenchymal tissue of a living organism. The cell formulation according to the present invention is considered to be based on a mechanism in which, for example, Muse cells are administered against interstitial cystitis having the abovementioned disorders to be successfully engrafted into affected bladder tissue, whereby the disorders are ameliorated and treated.
Owner:TOHOKU UNIV
Pluripotent stem cells for treatment of spinal cord infarction
PCT designated stageWO2025170054A1Nervous disorderUnknown materialsPluripotential stem cellSpinal cord
The purpose of the present invention is to provide a new medical use of pluripotent stem cells (Muse cells) in regenerative therapy. The present invention provides a cell preparation and a pharmaceutical composition for treating, preventing, alleviating and / or delaying onset of spinal cord infarction, comprising SSEA-3-positive pluripotent stem cells isolated from biologically derived mesenchymal tissues or cultured mesenchymal cells. The present invention is based on a mechanism in which Muse cells are administered to a subject having spinal cord infarction, and the cells are grafted to the tissue of the spinal cord infarction site, thereby treating spinal cord infarction.
Owner:TOHOKU UNIV
A method for preparing canine adipose-derived muse cells by magnetic bead sorting and application thereof
This invention belongs to the field of stem cell sorting technology and discloses a method for preparing canine adipose-derived MUSE cells using magnetic beads and its application. The method first involves digesting canine adipose tissue with collagenase and then expanding it by adhesion. Subsequently, FITC-labeled SSEA-3 antibody is combined with anti-FITC magnetic beads, and SSEA-3 positive cells are captured using EasySep™ column-free magnetic bead sorting technology. The sorted positive cells are then seeded into a microsphere culture apparatus containing 81 microwells for induction culture. Experiments show that the purity of the MUSE cells obtained by this method is over 90%, and the spontaneously reconstructed colonies (M-clusters) in the microwell system exhibit strong SSEA-3 fluorescent expression. This invention effectively solves the problems of low initial content of canine MUSE cells and significant damage during flow cytometry sorting, providing a high-quality source of seed cells for canine regenerative medicine treatment.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY
Method for inducing Muse cells to differentiate into pancreatic beta cell spheres through balling / adherent alternate culture and application
The invention relates to the technical field of cell engineering, in particular to a method for inducing Muse cells to differentiate into pancreatic beta cell spheres through balling / adherent alternate culture and application. Experimental results in the invention show that the Muse cells subjected to static balling culture are obvious in apoptosis due to hypoxia in spheres, and almost all the cells are apoptotic after being cultured for 23 days; the Muse cells subjected to direct adherent induction culture are high in proliferation capacity, and the differentiation efficiency is 37.7%; a balling and adherent alternate culture induction mode is adopted, so that stable passage can be realized, and the differentiation efficiency is 62.4%; the alternative culture induction method effectively solves the problems of proliferation and differentiation efficiency, and realizes stable passage and induced differentiation of the pancreatic beta cells.
Owner:SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI
Muse cell culture medium and culture method of umbilical cord-derived Muse cells
The invention belongs to the technical field of Muse cell culture, and discloses a Muse cell culture medium and a culture method of umbilical cord-derived Muse cells. According to the invention, a fibronectin and vitronectin composite matrix and an amplification culture medium A are used for adherent amplification of Muse cells, and the composite matrix can promote specific adhesion, spreading and proliferation of Muse cells. The maintenance medium B is used for recovering the Muse cell dryness, low-viscosity sodium alginate is used in the maintenance medium B to replace traditional methyl cellulose, the culture medium can remarkably improve the cell activity, and meanwhile the Muse cell dryness maintenance and recovery effect is better than that of a traditional MC culture medium. The amplification culture medium A and the maintenance culture medium B provided by the invention can be matched with a programmed amplification-maintenance circulating culture process, the SSEA-3 positive rate and the multidirectional differentiation potential of the cells are stably maintained for a long time while efficient amplification is performed, and the culture medium has a wide application prospect in large-scale Muse cell culture.
Owner:SHAANXI SENKAI TISSUE ENG & REGENERATIVE MEDICINE TECH CO LTD
Muse cell-derived protein complex, preparation method therefor, and use thereof
PCT designated stageWO2026077393A1Nervous disorderPeptide/protein ingredientsArthritisNeuro-degenerative disease
The present invention belongs to the field of biopharmaceuticals. Disclosed are a Muse cell-derived protein complex, a preparation method therefor, and use thereof. The composition of the protein complex is: a stem cell lysate of Muse cells after being cultured in a stress environment for a predetermined time, or a protein complex obtained by separating and purifying the stem cell lysate. The protein complex has a good cell damage repair effect, especially a strong ability to repair nerve cell damage, and is expected to be used for treating neurodegenerative diseases, cerebral stroke, cerebrovascular disease, arthritis, enteritis, recovery after trauma, autism, depression, and pulmonary fibrosis. In particular, the neurodegenerative diseases include, but are not limited to, Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and different types of spinocerebellar ataxia (SCA).
Owner:DARWIN BIOTECHNOLOGY (HUBEI) CO LTD
A method for inducing muse cells to differentiate into pancreatic beta cell spheroids through alternating spheroidization and adhesion culture and application thereof
The present application relates to the technical field of cell engineering, and particularly relates to a method for inducing Muse cells to differentiate into pancreatic beta cell spheroids through alternate spheroid formation and adhesion culture and application. Experimental results in the present application show that Muse cells cultured in static spheroids have obvious apoptosis due to lack of oxygen in the spheroids, and almost all cells are apoptotic after 23 days of culture; Muse cells directly induced by adhesion culture have strong proliferation ability, and the differentiation efficiency is 37.7%; and the Muse cells induced by alternate spheroid formation and adhesion culture not only can be stably passaged, but also have a differentiation efficiency of 62.4%; the alternate induction culture method effectively solves the problems of proliferation and differentiation efficiency, and realizes stable passage and induced differentiation of pancreatic beta cells.
Owner:SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI
Therapeutic agent of peripheral blood flow disorder
A cell product may be used for treating a peripheral blood flow disorder, and the cell product may include an SSEA-3-positive pluripotent stem cells (Muse cells) derived from a mesenchymal tissue in a living body or a cultured mesenchymal cell. The peripheral blood flow disorder is preferably a peripheral arterial disease, more preferably chronic arterial obstruction in a limb.
Owner:KYOTO PREFECTURAL PUBLIC UNIV CORP
Muse cell-derived protein complex as well as preparation method and application thereof
PendingCN121846145ANervous disorderPeptide/protein ingredientsNeuro-degenerative diseaseProtein-protein complex
The invention belongs to the field of biological medicines, and discloses a Muse cell-derived protein compound as well as a preparation method and application thereof, and the protein compound comprises the following components: stem cell lysate obtained after Muse cells are cultured for a preset time in a stress environment or a protein compound obtained by separating and purifying the stem cell lysate. The protein compound has a good cell injury repairing effect, especially has a strong repairing capability on nerve cell injury, is expected to be used for treating neurodegenerative diseases, cerebral apoplexy, cerebrovascular diseases, arthritis, enteritis, post-traumatic recovery, autism, depression and pulmonary fibrosis, and especially has a good application prospect in treatment of neurodegenerative diseases, cerebral apoplexy, cerebrovascular diseases, arthritis, enteritis, post-traumatic recovery, autism, depression and pulmonary fibrosis. The neurodegenerative diseases include, but are not limited to, Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), different types of spinal cerebellar ataxia (SCA).
Owner:DARWIN BIOTECHNOLOGY (HUBEI) CO LTD
Culture method for high-purity muse cells
PCT designated stage expiredWO2025112482A1Cell dissociation methodsSkeletal/connective tissue cellsCulture mediumsMuse cell
Provided is a culture method for high-purity Muse cells. The culture method comprises the following steps: S1, incubating mesenchymal stem cells with an SSEA3 primary antibody, performing centrifugation, removing a supernatant, adding immunomagnetic beads for incubation, and performing magnetic separation to obtain Muse cells; S2, culturing the Muse cells obtained in step S1 and a microcarrier in a culture medium under stirring at a rate of 40-60 r / min, performing digestion and passaging by means of using a pancreatic enzyme or protease, and replenishing the culture medium and the microcarrier; and S3, centrifugally washing the Muse cells cultured to third to sixth generations, detecting SSEA3 and CD105 phenotypes, performing cell counting, and performing cryopreservation. By means of combining the magnetic separation and microcarrier suspension culture, i.e. using the magnetic separation to improve the purity of Muse cells at the beginning, and then using the microcarrier to organically combine 3D spheroid culture and microsurface adherent culture, the present invention achieves amplification of 10 folds or more simple in about ten days, and the purity is higher than 80%. Therefore, the present invention can obtain high-purity Muse cells of clinical order of magnitudes in short time.
Owner:SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI
Agent for treating or preventing vascular dementia
An object is to provide a cell product for treating and / or preventing vascular dementia. The present invention provides a cell product for treating or preventing vascular dementia, containing a SSEA-3-positive pluripotent stem cell (Muse cell) derived from a mesenchymal tissue in a living body or a SSEA-3-positive pluripotent stem cell derived from a cultured mesenchymal cell.
Owner:TOHOKU UNIV
Method for enriching muse cells and obtaining exosomes, microvesicles or the secretome therefrom
The invention relates to a method of enriching Muse cells and obtaining the exosomes, microvesicles, or the secretome therefrom, in several embodiments, the exosomes, microvesicles, secretome or Muse cells may be used in therapeutic methods or non-therapeutic methods.
Owner:JLM EXOGRADE LLC